Archive · 2 Jun 2025
Delhi HC Restrains Dr. Reddy's in Novo Nordisk Weight Loss Drug Patent Case
Imagine a company that makes a special medicine for weight loss called Wegovy.
Another company tried to make a similar medicine using the same secret ingredient, semaglutide.
The first company, Novo Nordisk, has a patent, which is like a special protection for their idea.
Novo Nordisk went to court, and the court told the second company, Dr. Reddy's Laboratories, not to sell their version of the medicine in India for now.
Novo Nordisk is happy because they want to protect their idea.
The market for these medicines is growing fast in India.
It shows how important it is to protect the ideas of companies so they keep creating new medicines.
Delhi High Court has restrained Dr. Reddy's Laboratories and OneSource from marketing semaglutide in India.
The order follows a patent infringement suit filed by Novo Nordisk.
Novo Nordisk is preparing to launch its weight loss drug Wegovy in the Indian market.
Novo Nordisk stated it is taking steps to protect its inventions in India.
India's anti-obesity drug market has seen significant growth.
- Who
- Delhi High Court, Novo Nordisk, Dr. Reddy’s Laboratories, and OneSource.
- What
- The court restrained Dr. Reddy's and OneSource from marketing semaglutide.
- When
- The order was passed recently.
- Where
- Delhi High Court, India.
- Why
- Due to a patent infringement suit filed by Novo Nordisk.
Novo Nordisk
Dr. Reddy's Laboratories & OneSource
Patent Infringement
Novo Nordisk
They are patent infringers.
Dr. Reddy's Laboratories & OneSource
Likely to be concerned about the court's decision.
- Plaintiff
- Novo Nordisk
- Defendants
- Dr. Reddy's Laboratories, OneSource
- Active Ingredient
- Semaglutide
- Novo Nordisk's Drug
- Wegovy
- Issue
- Patent Infringement
- Market
- India
- Market Valuation (as of March 2025)
- ₹576 crore